Denver Corporate Center III
7900 East Union Avenue Suite 920
Denver, CO 80237
United States
720 437 6580
https://aytubio.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 150
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. Joshua R. Disbrow | Chairman & CEO | 660.51k | 無 | 1975 |
Mr. Mark K. Oki CPA | CFO, Secretary & Treasurer | 487.77k | 無 | 1969 |
Mr. Greg Pyszczymuka | Chief Commercial Officer | 489.78k | 無 | 1980 |
Ms. Margaret Cabano | Vice President of Operations | 無 | 無 | 無 |
Mr. Jarrett T. Disbrow Ph.D. | Chief Business Officer & President of Consumer Health | 331.19k | 無 | 1975 |
Mr. Russ McMahen | Senior Vice President of Research & Development | 無 | 無 | 無 |
Mr. Ryan J. Selhorn CPA | Executive VP of Finance & Business Optimization | 無 | 無 | 1982 |
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.
截至 無 止,Aytu BioPharma, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。